Vaccine file photo:XinhuaÂ A phase 2 trial of a COVID-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet. Massive changes to California voting spark fears of Iowa-style primary chaosAsian Americans wait for their turn to shine in HollywoodCal's epidemic protection services still have room for improvement